In vivo CAR T-cell Market Size is predicted to grow at a 32.9% CAGR during the forecast period for 2025-2034.
In vivo CAR T-cell therapy is a promising development in cancer immunotherapy, enabling the genetic modification of a patient’s T cells within the body to target cancer cells. Unlike traditional CAR T-cell therapies, which require extracting, modifying, and reinfusing T cells in a lab, in vivo methods use viral vectors (such as lentiviruses or AAV) or non-viral delivery systems (like lipid nanoparticles) to deliver CAR-encoding genes directly to immune cells. This technique enables for either long-term CAR expression or transient expression for regulated, repeated treatments.
The key market drivers for in vivo CAR T-cell therapy are shorter treatment times and cost efficiencies. This strategy speeds up treatment delivery by eliminating complex cell manufacturing and logistics, which are critical for rapidly growing malignancies. Furthermore, reducing dependency on lab-based methods reduces production costs and improves scalability, increasing patient access and presenting in vivo CAR T-cell therapy as a breakthrough oncology treatment.
Competitive Landscape
Some of the Key Players in In vivo CAR T-cell Market:
- Byterna Therapeutics
- Thunder Biotech
- Singular Immune
- NanoCell Therapeutics
- Jenthera Therapeutics
- Acuitas Therapeutics
- EsoBiotec (AstraZeneca)
- CDR3 Therapeutics
- Everest Medicines
- Mustang Bio
- Novartis
- Capstan Therapeutics
- Myeloid Therapeutics
- CARISMA Therapeutics
- Legend Biotech
- Innorna
- Genocury Biotech
- Abintus Bio
- Moderna
- Strand Therapeutics
- Coastar Therapeutics
- A Sail Biomedicines
- Orna Therapeutics
- Nona Biosciences
- Interius BioTherapeutics
- TriArm Therapeutics
- Sanofi
- AbbVie
- Shanghai Simnova Biotech
- Umoja Biopharma
- Astellas (Xyphos Biosciences)
- Theorna
- Kelonia Therapeutics
- Pregene
- bio
- EXUMA Biotech
- Sana Biotechnology
- Velvet Therapeutics
- Deliver Biosciences
- Vyriad
- Imanis Life Sciences
- CancerVAX
- IASO Bio
- Ensoma
Market Segmentation:
The In vivo CAR T-cell market is segmented by delivery systems and targets. By delivery systems, the market is segmented into lipid nanoparticles (LNPs), viral vectors, and oncolytic viruses. By target indication market is segmented into hematological cancers, solid tumors, non-oncology. By Target Antigen segment is categorized into CD19, BCMA, CD20, CD22, Others. By End User segment the market is segmented into Hospitals, Cancer Treatment Centers, Outpatient Clinics. The Payload Type segment comprises DNA-Based, mRNA-Based, Circular RNA (oRNA).
Viral Vectors Segment is Expected to Drive In vivo CAR T-cell Market
Viral vectors presently dominate the in vivo CAR T-cell market because of their excellent transfection efficiency, targeted delivery capability, and known safety profiles. Lentiviruses, retroviruses, and adeno-associated viruses (AAV) have been designed to selectively deliver CAR genes to T cells by modifying their envelope proteins or including targeting ligands. Their efficacy has been confirmed in preclinical and clinical trials, where lentiviral vectors expressing CD8+ or CD3+ T-cell-targeting transgenes effectively produced functional CAR T cells that proliferated and caused tumor regression in animal models.
AAV vectors have also demonstrated strong in vivo antitumor activity. Moreover, viral vectors enjoy scalable production through transient transfection in producer cell lines such as HEK-293T, and they possess an established regulatory record with multiple FDA-approved gene therapies, thus being a trusted and well-accepted platform for in vivo CAR T-cell applications.
Hematological Cancers Segment is Growing at the Highest Rate in the In vivo CAR T-cell Market.
The hematological cancers segment is the most rapidly growing and leading segment in the in vivo CAR T-cell market, primarily because of the early and successful use of CAR T-cell therapies in the treatment of blood cancers such as B-cell lymphomas, acute lymphoblastic leukemia (ALL), and multiple myeloma. These treatments have demonstrated robust clinical effectiveness, with several FDA-approved agents targeting antigens like CD19, resulting in sustained responses in patients with relapsed or refractory disease. Expansion in this segment is also driven by high unmet medical need, increasing global incidence of hematologic malignancies, and continued research focused on improving CAR T-cell persistence, safety, and accessibility through the expansion of clinical trials.
Regionally, North America Led the In vivo CAR T-cell Market.
North America now dominates the in vivo CAR T-cell market with the highest proportion of revenue share and innovation activity, fueled by its strong R&D infrastructure, particularly in the U.S., which has a high concentration of research institutions, biotech companies, and clinical trial sites specializing in CAR T-cell research.
The area is supported by a robust commercial foundation, favorable regulatory environments such as fast-track FDA routes, and positive reimbursement policies that drive the development and uptake of new therapies. Moreover, North America leads in the number of active clinical trials for in vivo CAR T-cell platforms and has an established healthcare infrastructure with specialized cancer treatment facilities that can adopt sophisticated immunotherapies.
In vivo CAR T-cell Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 32.9 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Delivery Systems, Target indication and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Byterna Therapeutics, Thunder Biotech, Singular Immune, NanoCell Therapeutics, Jenthera Therapeutics, Acuitas Therapeutics, EsoBiotec (AstraZeneca), CDR3 Therapeutics, Everest Medicines, Mustang Bio, Novartis, Capstan Therapeutics, Myeloid Therapeutics, CARISMA Therapeutics, Legend Biotech, Innorna, Genocury Biotech, Abintus Bio, Moderna, Strand Therapeutics, Coastar Therapeutics, A Sail Biomedicines, Orna Therapeutics, Nona Biosciences, Interius BioTherapeutics, TriArm Therapeutics, Sanofi, AbbVie, Shanghai Simnova Biotech, Umoja Biopharma, Astellas (Xyphos Biosciences), Theorna, Kelonia Therapeutics, Pregene, Alaya.bio, EXUMA Biotech, Sana Biotechnology, Velvet Therapeutics, Deliver Biosciences, Vyriad, Imanis Life Sciences, CancerVAX, IASO Bio, Ensoma. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
